Navigation Links
Regeneron Reports Fourth Quarter and Full Year 2012 Financial and Operating Results
Date:2/14/2013

utive Officer of Regeneron.  "With the recent U.S. approval of EYLEA for the treatment of macular edema following central retinal vein occlusion (CRVO), and receipt of a Medicare J-Code for EYLEA in January 2013, we expect continued strong U.S. growth for EYLEA and forecast U.S. net sales of $1.2 billion to $1.3 billion in 2013.  Outside the U.S., our partner Bayer HealthCare has begun to launch EYLEA for the treatment of neovascular age-related macular degeneration (wet AMD) in Japan, Europe, Australia, and other regions, and we expect to see substantial sales growth through 2013 and beyond as pricing approvals are received." 

"Clinical development of EYLEA in additional indications continued to progress in 2012, as the Phase 3 program in diabetic macular edema (DME) was fully enrolled and a Phase 3 trial in macular edema following branch retinal vein occlusion (BRVO) was initiated," said George D. Yancopoulos, M.D., Ph.D., Chief Scientific Officer, and President, Regeneron Laboratories.  "Our pipeline also advanced significantly during 2012, with the roll-out of our broad Phase 3 ODYSSEY program for REGN727, an antibody targeting PCSK9 to reduce low-density lipoprotein (LDL) cholesterol, and the full enrollment of our first Phase 3 trial for sarilumab, our IL-6 receptor antibody in rheumatoid arthritis.  We are also encouraged by the potential of our IL-4R inhibitor, REGN668.  REGN668 demonstrated positive proof of concept in allergic asthma and atopic dermatitis, and data from these trials will be submitted to medical conferences for presentation later in the year.  We look forward to starting later stage, Phase 2b trials with this antibody during 2013."

Business Highlights - Fourth Quarter 2012 and 2013 to Date EYLEA® (aflibercept) Injection for Intravitreal Injection

  • The Company and Bayer HealthCare collaborate on the global development and commercialization of EYLEA outside the U
    '/>"/>

  • SOURCE Regeneron Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

    Related medicine technology :

    1. Regeneron Announces Receipt of Hart-Scott-Rodino Notice
    2. Regeneron to Report Fourth Quarter and Full Year 2012 Financial and Operating Results and Host Conference Call and Webcast on February 14, 2013
    3. Regeneron Announces Presentation at the Deutsche Bank 2012 dbAccess BioFEST
    4. Sanofi and Regeneron Announce Patient Enrollment in Cardiovascular Outcomes Trial with Antibody to PCSK9 for Hypercholesterolemia
    5. Sanofi and Regeneron Announce Publication of Phase 2 Results with LDL Cholesterol-Lowering PCSK9 Antibody in the New England Journal of Medicine
    6. BioMed Realty Announces 80,500 Square Foot Lease Expansion For Regeneron Pharmaceuticals
    7. Regeneron Named Worlds #1 Biopharmaceutical Employer in Science Magazine Annual Survey
    8. Regeneron Announces September 2012 Investor Conference Presentations
    9. Regeneron to Report Second Quarter 2012 Financial and Operating Results and Host Conference Call and Webcast on July 25, 2012
    10. Regeneron Announces June 2012 Investor Conference Presentations
    11. Regeneron Provides Update On FDA Advisory Committee Discussion of ARCALYST® (rilonacept) Injection
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/20/2015)... WASHINGTON , April 20, 2015  In ... nation,s healthcare markets, the FTC announced that Cardinal ... it illegally monopolized 25 local markets for the ... hospitals and clinics to pay inflated prices for ... to pay $26.8 million of ill-gotten gains and ...
    (Date:4/20/2015)... April 20, 2015  Purdue Pharma, a leading ... Butcher has joined the company as Senior ... will have responsibility for all of Purdue,s efforts ... products that would benefit from our patient-focused commercial ... leader," said Purdue President & CEO Mark ...
    (Date:4/20/2015)... YORK , April 20, 2015 ... pump market will continue to be robust; the ... incidence of diabetes, expanding global markets, new product ... there are relatively steady market inhibitors, such as ... an increasing competitive environment. The healthcare market research ...
    Breaking Medicine Technology:Cardinal Health Agrees to Pay $26.8 Million to Settle Charges It Monopolized 25 Markets for the Sale of Radiopharmaceuticals to Hospitals and Clinics, says FTC 2Cardinal Health Agrees to Pay $26.8 Million to Settle Charges It Monopolized 25 Markets for the Sale of Radiopharmaceuticals to Hospitals and Clinics, says FTC 3Cardinal Health Agrees to Pay $26.8 Million to Settle Charges It Monopolized 25 Markets for the Sale of Radiopharmaceuticals to Hospitals and Clinics, says FTC 4Cardinal Health Agrees to Pay $26.8 Million to Settle Charges It Monopolized 25 Markets for the Sale of Radiopharmaceuticals to Hospitals and Clinics, says FTC 5Purdue Pharma Names J. Alan Butcher Senior Vice President of Licensing & Business Development 2Kalorama: Insulin Pump Market Growing Robustly 2Kalorama: Insulin Pump Market Growing Robustly 3
    ... TARRYTOWN, N.Y., Oct. 15 Regeneron Pharmaceuticals, Inc. (Nasdaq: ... the 17th Annual NewsMakers in the Biotech Industry Conference ... for 9:00 a.m. Eastern Time.  The session may be ... on the Investor Relations page.  An archived version of ...
    ... Oct. 15 EntreMed, Inc. (Nasdaq: ... for the treatment of cancer, today announced that ... Stock Market indicating that it has regained compliance ... Listed Securities ("MVLS") requirement for continued listing on ...
    Cached Medicine Technology:EntreMed Receives Notice of NASDAQ Compliance 2
    (Date:4/20/2015)... 1% for the Planet , one ... that Kate Williams, the network’s Director of Partnerships, will step ... Williams has been part of 1% for the Planet since ... of the Northern Forest Canoe Trail, a 1% for the ... the stewardship of and advocacy for the outdoors, a commitment ...
    (Date:4/20/2015)... 20, 2015 Today the members ... Research Fund-Ovarian Cancer National Alliance-National Ovarian Cancer Coalition ... Team will focus on “DNA Repair Therapies for ... identified DNA repair as a common weakness in ... and early detection of ovarian cancer by developing ...
    (Date:4/20/2015)... Grateful Dead originally formed in 1965 ... 1995. The group was more than just about rock music. ... space rock, country, and other genres to put together their ... The group was inducted into the Rock and Roll Hall ... than 35 million records worldwide. This year marks the ...
    (Date:4/20/2015)... New York (PRWEB) April 20, 2015 ... Centers for Medicare & Medicaid Services introduced their new ... HCAHPS (Hospital Consumer Assessment of Healthcare Providers and Systems) ... survey asks patients about their experiences during a recent ... results from July 1, 2013 through June 30, 2014 ...
    (Date:4/20/2015)... (PRWEB) April 20, 2015 Insuranceautoquote.info has ... find affordable car insurance quotes online . , ... for the best results. Clients should always compare online ... be done on a single website: . http://insuranceautoquote.info ... The questionnaire can be completed in a few minutes ...
    Breaking Medicine News(10 mins):Health News:1% for the Planet Announces New CEO 2Health News:1% for the Planet Announces New CEO 3Health News:New Ovarian Cancer Dream Team to Research DNA Repair Therapies 2Health News:New Ovarian Cancer Dream Team to Research DNA Repair Therapies 3Health News:New Ovarian Cancer Dream Team to Research DNA Repair Therapies 4Health News:Grateful Dead Tickets at Levi’s Stadium in Santa Clara: Ticket Down Slashes Grateful Dead Tickets in Santa Clara @ Levi’s Stadium for "Fare Thee Well" 50th Anniversary 2Health News:Northern Westchester Hospital Named a 5-Star Hospital In Medicare's Patient Satisfaction Rating 2Health News:Northern Westchester Hospital Named a 5-Star Hospital In Medicare's Patient Satisfaction Rating 3Health News:Affordable Auto Insurance Quotes Can Be Found Online, Fast and Easy 2
    ... BOSTON, Sept. 15 The 13th Annual ... (HFSA) today featured a discussion titled "Cardiovascular Disease in ... Chen, Director, Stress Echocardiography Program and Program for Cardiac ... Dr. Chen,s presentation highlights the increased risk of heart ...
    ... , , , ... HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ... use of Nexavar((R)) (sorafenib) tablets across tumor types - as ... will be presented at the joint 15th European CanCer Organisation ...
    ... CRANBURY, N.J., Sept. 15 Palatin Technologies, Inc. ... on clinical trial results with PL-3994, its product for heart ... Meeting of the Heart Failure Society of America in Boston. ... of PL-3994 in controlled hypertensive volunteers who were taking antihypertensive ...
    ... , , , ... abstract artist Susan Olmetti , one must only step ... step into the company of unconventional characters housed in an outlying charismatic ... mid-1800s and currently inhabited by more than 75 locally owned, independent businesses ...
    ... ALEXANDRIA, Va., Sept. 15 For overweight men ... cholesterol, high blood pressure, high blood sugar/glucose, poor diet and ... efforts to lose weight, according to Building Healthier America, a ... overweight and obesity in the U.S. , , ...
    ... , , , CAPE ... experiencing growth across a range of sectors. However, the drive ... medical imaging devices. , , (Logo: ... Frost & Sullivan ( http://www.medicaldevices.frost.com ), Overview ...
    Cached Medicine News:Health News:Presentation at Annual Meeting Highlights Increased Risk of Heart Failure in Childhood Cancer Survivors 2Health News:Presentation at Annual Meeting Highlights Increased Risk of Heart Failure in Childhood Cancer Survivors 3Health News:Bayer and Onyx Announce Nexavar Data Presentations at the Joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress 2Health News:Bayer and Onyx Announce Nexavar Data Presentations at the Joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress 3Health News:Bayer and Onyx Announce Nexavar Data Presentations at the Joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress 4Health News:Bayer and Onyx Announce Nexavar Data Presentations at the Joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress 5Health News:Bayer and Onyx Announce Nexavar Data Presentations at the Joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress 6Health News:Palatin Technologies, Inc. Announces PL-3994 Poster Presentation at 2009 Heart Failure Society of America Annual Meeting 2Health News:Palatin Technologies, Inc. Announces PL-3994 Poster Presentation at 2009 Heart Failure Society of America Annual Meeting 3Health News:Wine Reception Mixing up one Part Abstract Artist Susan Olmetti, one Part Chicago House Fundraiser, and one Part SIR Spa 2Health News:Building Healthier America Announces the 'High Five' Program Addressing Factors Affecting the Energy Levels of Overweight Men 2Health News:Building Healthier America Announces the 'High Five' Program Addressing Factors Affecting the Energy Levels of Overweight Men 3Health News:Medical Imaging Equipment Finds Significant Uptake in Ghana, Finds Frost & Sullivan 2Health News:Medical Imaging Equipment Finds Significant Uptake in Ghana, Finds Frost & Sullivan 3
    Sealing Mat for 96-well, 2.0ml, Deep Well, Square Available Sterile...
    96-well Silicone Compression Mat, Bulk...
    Silicone Compression Mat, Bulk...
    96-well Silicone Expansion Mat, Bulk...
    Medicine Products: